Treatment guidelines for gastrointestinal stromal tumors in children and young adults.
暂无分享,去创建一个
[1] C. Weldon,et al. Pediatric gastrointestinal stromal tumor. , 2012, Seminars in pediatric surgery.
[2] S. Baruchel,et al. Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study , 2011, Clinical Cancer Research.
[3] C. Antonescu,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.
[4] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[5] A. D. Van den Abbeele,et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.
[6] A. Pappo,et al. Pediatric gastrointestinal stromal tumors. , 2009, Hematology/oncology clinics of North America.
[7] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Scarpa,et al. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors , 2008, Journal of surgical oncology.
[10] Narasimhan P. Agaram,et al. Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.
[11] S. Hirohashi,et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Flieder,et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.
[13] R. Go,et al. Financial conflicts of interest (FCOIs) among the National Comprehensive Cancer Network (NCCN) clinical practice guideline panel members , 2008 .
[14] Narasimhan P. Agaram,et al. Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.
[15] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Fletcher,et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.
[17] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[18] R. DeMatteo,et al. Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model , 2006, Annals of surgery.
[19] L. Sobin,et al. Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases , 2006, The American journal of surgical pathology.
[20] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature , 2005, The American journal of surgical pathology.
[21] A. Pappo,et al. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs) , 2005, Pediatric blood & cancer.
[22] M. van de Rijn,et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Socci,et al. Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.
[24] B. Nilsson,et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.
[25] H. El‐Serag,et al. The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.
[26] M. Bernstein,et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.
[27] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[28] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[29] J. Fletcher,et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.
[30] J. Carney,et al. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. , 1999, Mayo Clinic proceedings.
[31] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[32] J. Ellison,et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.
[33] C. Antonescu,et al. Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors , 2006, Annals of Surgical Oncology.